ATM kinase inhibitor KU60019 dramatically accelerates both neuronal maturation and cellular senescence in human induced pluripotent stem cells, creating a powerful laboratory tool for modeling age-related diseases. The compound successfully triggered senescence-associated phenotypes in both neurons and fibroblasts, while enhancing disease-relevant characteristics in models of neurodegenerative conditions. This represents a significant methodological breakthrough for aging research. Current stem cell models require months or years to develop age-related features naturally, creating a major bottleneck in studying diseases like Alzheimer's and Parkinson's. KU60019 essentially fast-forwards this process, allowing researchers to study aged cellular phenotypes in dramatically compressed timeframes. The finding that these artificially aged cells depend on HSP90 survival pathways mirrors natural senescent cell biology, suggesting the model accurately recapitulates authentic aging mechanisms. While this is primarily a research tool rather than a therapeutic target, it could accelerate drug discovery for age-related diseases by providing more realistic cellular models. The approach may also reveal new insights about the ATM pathway's role in natural aging processes.